Lexicon Pharmaceuticals (LXRX) Total Liabilities (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) posted quarterly Total Liabilities of $66.0 million for Q1 2026, down 62.23% year-over-year from $174.6 million in Q1 2025, and down 14.83% quarter-over-quarter from $77.4 million in Q4 2025.
Lexicon Pharmaceuticals (LXRX) Total Liabilities (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has reported Total Liabilities for 17 consecutive years, with $66.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities fell 62.23% year-over-year to $66.0 million; the TTM figure through Mar 2026 stood at $66.0 million (down 62.23% YoY), while the FY2025 annual figure was $77.4 million, down 49.2% from the prior year.
- Total Liabilities eased to $66.0 million in Q1 2026 per LXRX's latest filing, from $77.4 million in the prior quarter.
- Across five years, Total Liabilities topped out at $174.6 million in Q1 2025 and bottomed at $41.5 million in Q2 2022.
- Historically, Total Liabilities has averaged $102.6 million across 5 years, with a median of $96.1 million in 2025.
- Annual changes were most pronounced in 2022 — Total Liabilities jumped 231.02% — and 2026, when it sank 62.23%.
- Lexicon Pharmaceuticals' Total Liabilities stood at $77.2 million in 2022, then soared by 76.64% to $136.3 million in 2023, then rose by 11.85% to $152.5 million in 2024, then plunged by 49.2% to $77.4 million in 2025, then dropped by 14.83% to $66.0 million in 2026.
- Business Quant data shows LXRX's Total Liabilities at $66.0 million in Q1 2026, $77.4 million in Q4 2025, and $85.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Lexicon Pharmaceuticals | 1.04 Bn | 846.13 Mn | 653,000.00 | 75.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 75.54 Mn |
| Mar 31, 2026 | 65.96 Mn |
| Dec 31, 2025 | 77.45 Mn |
| Sep 30, 2025 | 85.77 Mn |
| Jun 30, 2025 | 96.14 Mn |
| Mar 31, 2025 | 174.64 Mn |
| Dec 31, 2024 | 152.47 Mn |
| Sep 30, 2024 | 142.61 Mn |
| Jun 30, 2024 | 133.38 Mn |
| Mar 31, 2024 | 128.35 Mn |
| Dec 31, 2023 | 136.32 Mn |
| Sep 30, 2023 | 136.97 Mn |
| Jun 30, 2023 | 130.36 Mn |
| Mar 31, 2023 | 74.67 Mn |
| Dec 31, 2022 | 77.18 Mn |
| Sep 30, 2022 | 47.67 Mn |
| Jun 30, 2022 | 41.50 Mn |
| Mar 31, 2022 | 43.48 Mn |
| Dec 31, 2021 | 23.31 Mn |
| Sep 30, 2021 | 35.73 Mn |